ArticleFrontiers in aging neuroscience2026
Progression of
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic architecture and molecular pathogenesis of Parkinson's disease: emerging mechanisms and therapeutic targets.Metabolic brain disease · 2026Review
- Selective Neuronal Vulnerability to Alpha-Synuclein Pathology in Parkinson's Disease: A Critical Review of Mechanistic Rationale and Biomarker Stratification.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: An association between severe Methods: We assessed symptom progression in individuals with severe and PD-risk variants compared to non-carriers. We analyzed longitudinal data from 726 individuals with typical PD, including 22 carriers of severe Results: The findings were not significant after adjusting for Bonferroni correction; however, linear mixed models analyses showed that at a nominal significance level of 5%, carriers of PD-risk or severe variants were associated with faster cognitive decline compared to non-carriers. Moreover, carriers of PD-risk variants were associated with faster worsening of apathy, quality of sleep, tremor, and non-motor symptoms [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS I)] compared to non-carriers; however, we did not observe this tendency in individuals with severe variants. Discussion: The exploratory study suggests associations between PD-risk variants and a more rapid disease progression among carriers compared to non-carriers. Nevertheless, the findings should be interpreted cautiously and require confirmation in an independent cohort before any reevaluation of their pathologic relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.